Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

Parellada, Eduard; Andrezina, R.; Milanova, Vihra; Glue, P.; Masiak, Marek; Turner, Mark; Medori, R.; Gäebel, Wolfgang

doi:10.1177/0269881105056513

Public

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

Published in Journal of Psychopharmacology • Sep 1, 2005

Authors:

Eduard Parellada

R. Andrezina

Vihra Milanova

Abstract

The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years). Patients who required a treatment change received RLAI (2-weekly gluteal injections of 25, 37.5 or 50 mg, per clinica...

Subject

Risperidone

Tolerability

Schizophrenia (object-oriented programming)

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!